Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced an inducement stock option grant. The grant, approved by the Company's Compensation Committee on April 17, 2025, allows a new non-executive employee to purchase 5,000 shares of common stock.
The option's exercise price matches Autonomix's closing price on the Nasdaq Capital Market on April 17, 2025. The grant features a ten-year term and vests in four equal annual installments, contingent upon the employee's continued employment with the company through the vesting dates. This grant was made under Nasdaq Rule 5635(c)(4) as part of the employee's compensation package.
Autonomix Medical (NASDAQ: AMIX), un'azienda di dispositivi medici specializzata nelle tecnologie per la diagnosi e il trattamento delle malattie del sistema nervoso, ha annunciato una concessione di opzioni azionarie di incentivo. La concessione, approvata dal Comitato per la Retribuzione della Società il 17 aprile 2025, consente a un nuovo dipendente non dirigente di acquistare 5.000 azioni ordinarie.
Il prezzo di esercizio dell'opzione corrisponde al prezzo di chiusura di Autonomix sul Nasdaq Capital Market del 17 aprile 2025. La concessione prevede un termine di dieci anni e si matura in quattro rate annuali uguali, subordinatamente alla permanenza del dipendente in azienda fino alle date di maturazione. Questa concessione è stata effettuata ai sensi della Regola Nasdaq 5635(c)(4) come parte del pacchetto retributivo del dipendente.
Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos especializada en tecnologías para el diagnóstico y tratamiento de enfermedades del sistema nervioso, ha anunciado una concesión de opciones sobre acciones como incentivo. La concesión, aprobada por el Comité de Compensación de la Compañía el 17 de abril de 2025, permite a un nuevo empleado no ejecutivo comprar 5,000 acciones ordinarias.
El precio de ejercicio de la opción coincide con el precio de cierre de Autonomix en el Nasdaq Capital Market el 17 de abril de 2025. La concesión tiene un plazo de diez años y se otorga en cuatro cuotas anuales iguales, condicionadas a que el empleado continúe trabajando en la empresa hasta las fechas de adjudicación. Esta concesión se realizó bajo la Regla Nasdaq 5635(c)(4) como parte del paquete de compensación del empleado.
Autonomix Medical(NASDAQ: AMIX)는 신경계 질환 진단 및 치료 기술을 전문으로 하는 의료기기 회사로, 유인 주식매수선택권 부여를 발표했습니다. 이 부여는 2025년 4월 17일 회사 보상위원회에서 승인되었으며, 신임 비임원 직원이 5,000주의 보통주를 매입할 수 있도록 허용합니다.
옵션의 행사 가격은 2025년 4월 17일 나스닥 캐피탈 마켓에서 Autonomix의 종가와 동일합니다. 이 부여는 10년 만기이며, 직원이 계속 근무하는 조건 하에 4년간 동일한 연간 할부로 권리가 취득됩니다. 이 부여는 직원 보상 패키지의 일환으로 나스닥 규칙 5635(c)(4)에 따라 이루어졌습니다.
Autonomix Medical (NASDAQ : AMIX), une société de dispositifs médicaux spécialisée dans les technologies de diagnostic et de traitement des maladies du système nerveux, a annoncé l'octroi d'options d'achat d'actions incitatives. Cet octroi, approuvé par le Comité de Rémunération de la Société le 17 avril 2025, permet à un nouvel employé non cadre d'acheter 5 000 actions ordinaires.
Le prix d'exercice de l'option correspond au cours de clôture d'Autonomix sur le Nasdaq Capital Market le 17 avril 2025. L'octroi prévoit une durée de dix ans et se consolide en quatre versements annuels égaux, sous réserve que l'employé reste en poste jusqu'aux dates d'acquisition. Cet octroi a été réalisé conformément à la règle Nasdaq 5635(c)(4) dans le cadre du package de rémunération de l'employé.
Autonomix Medical (NASDAQ: AMIX), ein Unternehmen für medizinische Geräte, das sich auf Technologien zur Diagnose und Behandlung von Erkrankungen des Nervensystems spezialisiert hat, hat eine Gewährung von Aktienoptionen als Anreiz bekannt gegeben. Die Gewährung, die vom Vergütungsausschuss des Unternehmens am 17. April 2025 genehmigt wurde, erlaubt einem neuen nicht-exekutiven Mitarbeiter den Kauf von 5.000 Stammaktien.
Der Ausübungspreis der Option entspricht dem Schlusskurs von Autonomix am Nasdaq Capital Market am 17. April 2025. Die Gewährung hat eine Laufzeit von zehn Jahren und wird in vier gleichen jährlichen Raten unverfallbar, vorausgesetzt, der Mitarbeiter bleibt bis zu den jeweiligen Vesting-Terminen im Unternehmen beschäftigt. Diese Gewährung erfolgte gemäß Nasdaq-Regel 5635(c)(4) als Teil des Vergütungspakets des Mitarbeiters.
- None.
- None.
THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix’s Board of Directors approved the grant of an inducement stock option on April 17, 2025 to purchase 5,000 shares of the Company’s common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual’s employment compensation and was granted as an inducement material to their start of employment with the Company.
The option has an exercise price equal to the closing price of Autonomix’s common stock as reported by the Nasdaq Capital Market on April 17, 2025. The options have a ten-year term and vest in four equal annual installments, subject to the employee’s continued services to the Company through the applicable vesting dates.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, to submit and receive approval of an IDE, and to file a De Novo application. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What are the terms of AMIX's new inducement stock option grant announced on April 17, 2025?
How does the vesting schedule work for AMIX's new employee stock option grant?
What is the purpose of AMIX's inducement grant under Nasdaq Rule 5635(c)(4)?
How many shares are included in AMIX's April 2025 inducement stock option grant?
